Project Grant 1951153

Partillion Bioscience Corp. was awarded a $659,037 Project Grant from the National Institutes of Health's National Institute of General Medical Sciences to develop reagent products enabling high-throughput screening and selection of single cells based on secreted bio-products. Under the Biomedical Research and Research Training program (CFDA 93.859), Partillion plans to transition its lab-on-a-particle technology—highlighted as a 2020 SLAS Innovation Award winner—into the first reagent product...

This SBIR Phase I project, funded by a $305,000 award from the National Science Foundation's (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program, aims to develop a microchip-based technology for complex, multidimensional cell reprogramming. The project seeks to create a miniaturized liquid and cell handling system that leverages acoustic-electric micro-vortices to precisely and sequentially deliver genetic molecules, making advanced cell engineering more accessible across...

The National Cancer Institute has awarded a $275,627 Project Grant to Link Biosystems Inc., a self-certified small disadvantaged business and for-profit organization, to develop the ONXPANSION bioreactor workflow. This workflow aims to enable efficient expansion of patient-derived induced pluripotent stem cells into clinically relevant cell doses to support autologous cell therapy applications. The grant supports efforts to de-risk the utility of Link Biosystems' bioreactor technology for...

This SBIR Phase I project, awarded by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program, aims to develop an automated system to streamline the sample preparation process for liquid biopsy cancer testing. The $305,000 award will fund the creation of a microfluidic-based instrument that automates the bisulfite conversion step, a critical but time-consuming and error-prone process in preparing circulating tumor DNA for epigenetic...

Rattan Life Science Inc. received a $275,000 Project Grant award from the National Science Foundation under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to develop a platform for generating induced pluripotent stem cell-derived naïve CD4+ and CD8+ T cells with fidelity, reproducibility and scalability. The platform employs proprietary induced thymic epithelial cells to provide biologically relevant thymic positive selection signals during T cell differentiation,...

This $295,924 Project Grant awarded by the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859) aims to develop and demonstrate a high-yield microfluidic device for the enrichment and capture of CD3+ T cells. This device is intended to improve the manufacturing of autologous and allogenic engineered cell therapies such as CAR-T, which currently have time-consuming and costly production processes. The key objectives are to (1)...

This $568,264 Project Grant (R41HL178144) was awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) to SAFI Biotherapeutics Inc., a pre-clinical blood cell therapy company based in Cambridge, MA. The goal of this Phase I STTR project is to develop a scalable bioprocess for manufacturing designer red blood cells (RBCs) derived from induced pluripotent stem cells (iPSCs). These designer RBCs will serve as reagents to...

This $125,805 Project Grant award from the National Science Foundation (NSF) Engineering program (CFDA 47.041) aims to develop new cell sorting technologies that can identify and separate cells based on changes in the activity of naturally occurring light-emitting molecules like NAD(P)H. The goal is to enable label-free, rapid identification and purification of cell populations, with a focus on stem cells and their functional subsets. The research will create a single cell deposition module to...

This $500,000 Project Grant from the National Science Foundation Division of Molecular and Cellular Biosciences, under the Biological Sciences federal grant program (CFDA 47.074), will support research to develop an end-to-end continuous manufacturing process for cell therapies using robotics and microfluidic technologies. The Georgia Tech Research Corporation will receive funding to create a more integrated workflow based on microfluidic device-enabled genetic engineering, cell expansion, and...

This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $275,396 to Link Biosystems Inc., a self-certified small disadvantaged business, to develop bioreactor technologies for efficient differentiation, scale-up, and maturation of induced pluripotent stem cell (iPSC)-derived cardiomyocytes. The research aims to address challenges in producing clinically relevant quantities of...